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Citalopram ampliﬁes the inﬂuence of living conditions on
mood in depressed patients enrolled in the STAR*D study
F Chiarotti1,4, A Viglione1,4, A Giuliani2 and I Branchi1,3
Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressant drugs, have a variable and
incomplete efﬁcacy. In order to better understand SSRI action, we explored the hypothesis that SSRIs do not affect mood per se but
amplify the inﬂuence of the living conditions on mood. To this aim, we exploited the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment
outcome according to dosage − 20 or 40 mg per day of citalopram. We found that sociodemographic characteristics affected
treatment response in the same direction in the two dose groups, but these effects reached statistical signiﬁcance only in the
40 mg per day dose group. In the latter, higher improvement rate was associated with having a working employment status
(P= 0.0219), longer education (P= 0.0053), high income (P= 0.01) or a private insurance (P= 0.0031), and the higher remission rate
was associated with having a working employment status (P= 0.0326) or longer education (P= 0.0484). Moreover, the magnitude of
the effect of the sociodemographic characteristics on mood, measured as the percent of patients showing a positive outcome
when exposed to favorable living conditions, was much greater—up to 37-fold—in the 40 compared to the 20 mg per day dose
group. Overall, our results indicate that citalopram ampliﬁes the inﬂuence of the living conditions on mood in a dose-dependent
manner. These ﬁndings provide a potential explanation for the variable efﬁcacy of SSRIs and might lead to the development of
personalized strategies aimed at enhancing their efﬁcacy.
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INTRODUCTION
Antidepressant drugs are the current standard treatment for major
depressive disorder (MDD) and, among these, selective reuptake
inhibitors (SSRIs) are the most commonly prescribed. However,
their efﬁcacy is variable and incomplete: 60–70% of depressed
patients do not experience remission and 30–40% do not show
a signiﬁcant response.1 One of the main reasons for such
incomplete efﬁcacy is the poor comprehension of their mechan-
isms of action. A new hypothesis, the undirected susceptibility to
change hypothesis, predicts that SSRI treatment does not drive
changes in mood per se but, by increasing brain plasticity, creates
a window of opportunity for a change in mood that is driven by
the quality of the living conditions.2 In particular, the serotonin
increase induced by SSRIs enhances brain plasticity and thus
renders the individual more susceptible to the inﬂuence of the
living conditions. The main consequence is the lack of a univocal
outcome of SSRI administration: in a favorable environment
treatment leads to a reduction of symptoms; by contrast, in a
stressful environment it may lead to a worse prognosis. As a
further consequence, SSRIs are expected to amplify the inﬂuence
of living conditions on mood in a dose-dependent manner. Such
hypothesis is supported by preclinical data3–5 showing that
ﬂuoxetine treatment leads to an improvement of the
depression-like phenotype when administered in an enriched
condition, while it leads to a worsening when administered in a
stressful condition. In addition, SSRI treatment consequences on
selected end points, such as vulnerability to obesity, have been
shown to be dependent on the quality of the environment.6,7
Finally, a number of clinical studies have shown that the
environment moderates the effects of antidepressant
treatment.1,8–13 However, the approaches used so far in these
studies do not allow for assessing the effect of SSRIs on the
susceptibility to the inﬂuence of the living conditions.
The main aim of the present study was to test whether SSRI
treatment ampliﬁes the inﬂuence of the living conditions on mood
in a dose-dependent manner. We thus exploited the data
collected in the framework of the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) study. We considered
a subpopulation of 591 patients having similar MDD severity and
overlapping treatment history, and analyzed the efﬁcacy of
treatment between weeks 4 and 6 according to the dose
received—either 20 or 40 mg per day of citalopram. Longer or
different treatment periods or other patients’ groups could not be
considered without losing data validity because of the limitations
imposed by the STAR*D trial design. The socioeconomic
characteristics included in the analysis are proxy of the quality
of the patient's life environment and widely considered reliable
indicators of socioeconomic status.14 Our prediction was that the
40 mg per day dose, compared to the 20 mg per day dose, would
amplify the inﬂuence of sociodemographic characteristics on
patients’ mood, since it should increase plasticity to a higher
degree and thus lead to greater susceptibility to the environment.
We therefore predicted citalopram to affect susceptibility to the
living conditions in a dose-dependent manner. In addition, since
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we hypothesized that the environment drives the change in MDD
induced by SSRIs, we predicted that patients living in conditions
associated to a high quality of life should show a more effective
response to treatment.
MATERIALS AND METHODS
Study organization
This paper is based on the STAR*D (ClinicalTrials.gov, number
NCT00021528) study data. The design details of STAR*D are described
accurately elsewhere.15 In brief, STAR*D was a multisite, prospective,
randomized, multistep clinical trial conducted in the United States of
America aimed to determine which of several treatments would be most
effective for outpatients with nonpsychotic MDD.16 The study was
conducted at 18 primary care and 23 psychiatric care centers and enrolled
4041 nonpsychotic MDD patients, aged 18–75, with a baseline score ⩾ 14,
on the 17-item Hamilton Depression Rating Scale (HAM-D17).
MDD symptom severity in the STAR*D clinical trial was measured
longitudinally using the 16-item Quick Inventory of Depressive Sympto-
matology (QIDS). The QIDS is a briefer version of the more commonly used
30-item Inventory of Depressive Symptomatology—IDS. The QIDS is
available in the clinician and self-rated version and has been designed to
assess the severity of depressive symptoms through the evaluation of all
the criterion symptom domains designated by the American Psychiatry
Association Diagnostic and Statistical Manual of Mental Disorders—4th
edition (DSM-IV) to diagnose a major depressive episode. Each item was
scored on a scale from 0 to 3 points: 0 indicating no problem and 3
indicating severe problem. Total score ranges from 0, that is, not
depressed, to 27, that is, most depressed. For further details on the
validity, reliability, generalizability, scoring and interpretation, see http://
www.ids-qids.org/.
Treatment
At Level 1, all participants were treated with citalopram, a SSRI, for a
minimum of 8 weeks and were encouraged to complete 12 weeks to
maximize beneﬁt. All participants started treatment with a dose of 20 mg
per day citalopram, with clinical visits at 2, 4, 6, 9 and 12 weeks. To ensure
satisfactory dosing for an appropriate period of time, treatment
was conducted using measurement-based care. This included ﬂexible
dosing recommendations based on symptom and side effect at
each treatment visit.17 According to the Guidelines for discontinuing
participants from the randomized treatment study, patient drop out could
be due to a number of reasons including participant request and decision
by clinicians to discontinue the study is in the best interest of the
participant.
Dose adjustments were decided according to the QIDS-Clinician-rate
(QIDS-C16) score: QIDS-C16⩽ 5, continue current dose; QIDS-C16= 6–8,
continue or increase current dose according to the clinician assessment;
QIDS-C16⩾ 9, increase current dose. In addition, if the reduction in
baseline symptom severity was found to be o20% at week 4, the initial
dose (20 mg per day) was raised to 40 mg per day, assuming tolerable side
effects. At week 4, participants with intolerable side effects could move to
the next treatment level.17
Selection criteria
In the present study, data from level 1 of STAR*D were considered. Only
patients having similar MDD severity and overlapping treatment history
were included in the analysis. In particular, we selected patients treated
with a dose of 20 mg per day for the ﬁrst 4 weeks following enrollment,
showing a QIDS-SR16 score equal to 6–10 (mild depression) on week 4 and
whose information concerning the QIDS score on week 6 was available
(Supplementary Figure S1). Longer or different treatment periods or other
patients’ groups could not be considered without losing data validity
because of the limitations imposed by the STAR*D trial design. In
particular, according to the recommendations of the clinical trial design,
patients with high QIDS score that indicates moderate, severe and very
severe depression are compulsorily assigned to a dose increase. Including
patients with all QIDS scores in the analysis would lead to bring severe
depressed and potentially non-responding patients in the high dose
group, erroneously leading to the conclusion that the high dose is less
effective. The subset of patients considered in the present study show no
meaningful clinical difference in depressive symptomatology (measured as
QIDS-SR16 score at enrollment, at week 4 and as difference between week
4 and enrollment) according to the dose assignment (see Results section
and Table 1). We therefore analyzed treatment efﬁcacy between weeks 4
and 6 according to the dose received, either 20 or 40 mg per day of
citalopram.
Sociodemographic characteristics
The efﬁcacy of the two dosing regimens was analyzed in relation to a
number of sociodemographic characteristics considered as proxy of the
socioeconomic status and the quality of the living environment of the
patient:14 sex, race, marital status, employment status, insurance status,
education, income, experience of traumatic events and drug abuse. In
addition, we analyzed the following descriptors of the onset and
progression of the psychopathology: age at onset of ﬁrst major depressive
episode (MDE), number of MDE, difference in QIDS-SR16 score between
enrollment and week 4. Education was shown as years of schooling
completed; we considered two levels of education: ocollege (o16 years)
and ⩾ college (⩾16 years). Income was analyzed subdividing the examined
population into three monthly income classes: the low-income group was
set at ⩽ $1000, while middle and high income groups at $1000–$2500 and
4$2500, respectively. Employment status was analyzed considering only
two conditions: employed (self-employed, part-time employed and full-
time employed) and unemployed (unemployed and retired). For marital
status we considered: never married, married (married or cohabiting) and
no more married (separated, divorced and widowed). Finally, we
considered only two ethnicities, Caucasian (white) and non-Caucasian (all
other ethnicities).
Outcome measures
MDD symptom severity was measured using the QIDS-SR16. Remission was
deﬁned as a QIDS-SR16 score ⩽ 5. In order to determine the effects of
citalopram treatment, according to sociodemographic characteristics, we
considered three variables: (i) percent of patients showing an improve-
ment, measured as a reduction ⩾ 1 in QIDS-SR16 score between week 4
and 6; (ii) percent of patients achieving remission, measured as the
attainment of a QIDS-SR16 score ⩽ 5 at week 6; and (iii) variation in the
QIDS-SR16 score, measured between weeks 4 and 6.
Data analysis
Of the 4041 participants, a sample of 591 patients was identiﬁed according
to the selection criteria (Supplementary Figure S1). Summary statistics are
presented as percentages for discrete variables, and as means and s.d. for
continuous variables. Logistic regression models were used to assess the
association of all sociodemographic characteristics with QIDS-SR16 score
improvement and remission rate, within each dose group, and to compute
odds ratios. The Wald test was used to compute the overall signiﬁcance of
the categorical sociodemographic factors presenting more than two levels.
The use of the odds ratios as a measure of risk is debatable and its
approximation to the relative risk (RR) is acceptable only when the risk of
the event (in the present study, the improvement or remission) in the
control group (in the present study, the favorable sociodemographic
condition) is very low, that is, under the so-called 'rare disease
assumption'.18 For this reason, we additionally computed the percent of
improvement or remission in the favorable (that is, associated to a high
quality of life) and in the unfavorable (that is, associated to a low quality of
life) sociodemographic condition, and the RR of unfavorable versus
favorable condition, with the corresponding 95% conﬁdence interval.
Finally, the preventive fraction (1− RR) was computed to estimate the
effect size and thus the magnitude of inﬂuence of the living conditions on
the outcome. As in our study the outcome measured is a beneﬁcial one,
that is improvement or remission, values of 1− RR40 indicate that the
unfavorable condition decreases the probability of the beneﬁcial outcome
compared to the favorable condition, and vice versa. The variation in the
QIDS-SR16 score between weeks 4 and 6 was analyzed with analyses of
variance including sociodemographic characteristics as between-subject
factors. Separate analyses of variance were performed for each socio-
demographic characteristic within the two treatment doses. Post hoc
comparisons were performed using the Tukey’s test. The variation in
percent of improvement, stationary and worsening according to socio-
demographic characteristics has been analyzed independently in the two
dose groups with Χ2-test.
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RESULTS
Baseline characteristics
Of 591 patients who comprised the evaluable sample, 357 (60.4%)
were treated with 20 mg of citalopram per day and 234 (39.6%)
with 40 mg of citalopram per day between weeks 4 and 6.
Females comprised two-thirds of the sample and minority
representation was robust. The two dose groups did not show
any meaningful clinical difference before receiving different
citalopram doses (Supplementary Table S1). At enrollment, their
QIDS-SR16 scores were almost overlapping (20 mg per day dose
group: mean 14.14, s.d. 3.78; 40 mg per day dose group: mean
14.7, s.d. 3.79). The two groups did not differ also in QIDS-SR16
score at week 4 (20 mg per day dose group: mean 7.93, s.d. 1.39;
40 mg per day dose group: mean 8.16, s.d. 1.44). Finally, as shown
in Table 1, no difference between the 20 and 40 mg per day dose
groups was found in response to treatment as both showed an
Table 1. Baseline sociodemographic characteristic of the evaluable sample by citalopram dose
Baseline characteristics Citalopram dose
N= 591 (%) 20 mg per die; N= 357 (60.4%) 40 mg per die; N= 234 (39.6%)
Ethnicity
Non-Caucasiana 165 (27.9) 108 (30.3) 57 (24.4)
Caucasian 426 (72.1) 249 (69.7) 177 (75.6)
Sex
Female 362 (61.3) 222 (62.2) 140 (59.8)
Male 229 (38.7) 135 (37.8) 94 (40.2)
Marital status
No more married 125 (25.8) 77 (26.1) 48 (25.4)
Never married 140 (28.9) 86 (29.2) 54 (28.6)
Married 219 (45.2) 132 (44.7) 87 (46.0)
Employment status
Unemployed and retired 185 (38.2) 110 (37.3) 75 (39.7)
Employed 299 (61.8) 185 (62.7) 114 (60.3)
Educationb
oCollege 294 (60.7) 180 (61.0) 114 (60.3)
⩾College 190 (39.3) 115 (39.0) 75 (39.7)
Incomec
Low 172 (29.9) 105 (30.3) 67 (29.4)
Middle 195 (33.9) 114 (32.9) 81 (35.5)
High 208 (36.2) 128 (36.9) 80 (35.1)
Experienced traumatic event
No 333 (56.8) 203 (57.3) 130 (56.0)
Yes 253 (43.2) 151 (42.7) 102 (44.0)
Witnessed traumatic event
No 405 (69.1) 241 (68.1) 164 (70.7)
Yes 181 (30.9) 113 (31.9) 68 (29.3)
Drug abuse
No 129 (95.6) 73 (97.3) 56 (93.3)
Yes 6 (4.4) 2 (2.7) 4 (6.7)
Insurance status
Public insurance 39 (8.0) 25 (8.6) 14 (7.4)
No insurance 179 (36.8) 103 (35.3) 76 (40.4)
Private insurance 269 (55.2) 164 (56.2) 98 (52.1)
Median (observed range) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Age (years) 41.0 (18–75) 41.3 (13.3) 41.3 (13.6) 41.1 (12.8)
Years of education 14.0 (1–25) 14.3 (9.5) 14.2 (3.4) 14.5 (3.0)
Income ($ per month) 1 900 (0–50 000) 2794 (3620) 2670 (2785) 2982 (4610)
Age at onset of ﬁrst MDE 22.0 (4–73) 26.3 (14.6) 27.0 (15.1) 25.1 (13.8)
Number of MDEs 3.0 (1–84) 5.6 (9.1) 5.3 (7.7) 6.0 (10.8)
QIDS-SR16 (difference W4− Enroll) − 6 (−19–7) − 6.4 (3.9) − 6.2 (3.9) − 6.6 (3.9)
Abbreviations: MDE, major depressive episode; QIDS-SR16, Quick Inventory of Depressive Symptomatology-Self-Report. aAsian, American Indian or Alaskan
Native, Native Hawaiian/Other Paciﬁc Islander or multiracial. boCollege=⩽ 16 years of schooling; ⩾College=⩾16 years of schooling. cLow=monthly gain
⩽ $1000; Middle=monthly gain $1000–$2500; High=monthly gain 4$2500.
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almost overlapping reduction of QIDS-SR score during the ﬁrst
4 weeks of treatment, when all patients received the 20 mg
per day dose. Table 1 summarizes further baseline characteristics
of the two groups.
Sociodemographic characteristics and dosage associated with
improvement
According to our hypothesis, the two citalopram dosages
ampliﬁed the inﬂuence of sociodemographic characteristics on
the percent of patients showing an improvement in a dose-
dependent manner. In the 20 mg per day dose group, patients'
response was not signiﬁcantly affected by sociodemographic
characteristics. By contrast, in the 40 mg per day dose group,
sociodemographic characteristics were associated to signiﬁcantly
different outcomes. In the latter group, a higher rate of
improvement was associated with having a working employment
status, more than 16 years of education, high income and a
private insurance (Table 2). In order to appreciate the inﬂuence of
the environment in each dose group, its magnitude was measured
as the preventive fraction (1− RR). The comparison of the
preventive fraction, indicating the percent of patients showing a
positive outcome when exposed to a favorable environment,
between the two dose groups shows that the inﬂuence of
sociodemographic characteristics on treatment outcome was
overall markedly higher in the 40 mg per day dose group. In
particular, the magnitude of the inﬂuence of the employment
status (unemployed versus employed) and education (ocollege
versus ⩾ college) on improvement rate was, respectively, 5- and
37-fold in the 40 compared to the 20 mg per day dose group. In
addition, the magnitude of the inﬂuence on improvement rate of
income was 6- (high versus low) and 8-fold (high versus middle)
and of insurance was 22- (no versus public) and 8-fold (private
versus public) in the 40 compared to the 20 mg per day group
(Supplementary Table S2).
Rate of remission
As for the rate of improvement, the two citalopram dosages
produced a different ampliﬁcation of the inﬂuence of the socio-
demographic characteristics on the percent of patients achieving
remission. In particular, in the 40mg per day group, a signiﬁcantly
higher rate of remission was found to be associated with being
employed and having longer education (Table 3). The magnitude of
the inﬂuence of the employment status (unemployed versus
employed) and education (ocollege versus ⩾ college) on remission
rate was, respectively, six- and twofold in the 40 compared to the
20 mg per day group (Supplementary Table S3).
Variation in the QIDS-SR16 score
The variation in the QIDS-SR16 score produced results in line with
the previous ones, as it signiﬁcantly differed according to
sociodemographic variables only in the 40 mg per day dose
group. In particular, in this group, being of Caucasian ethnicity
(F (1,232) = 5.334, P= 0.0218), having a private insurance
(F (2,185) = 4.427, P= 0.0132), a high income (F (2,225) = 3.629,
P= 0.0281) or more years of education (F (1,187) = 11.344,
P= 0.0009) was associated with a signiﬁcant larger reduction of
QIDS-SR16 score (Figure 1). Post hoc analysis revealed a signiﬁcant
reduction of the QIDS-SR16 comparing high versus low income
(Po0.05) and having a private versus a public insurance
(Po0.05).
DISCUSSION
The results of the present study show that citalopram ampliﬁes
the inﬂuence of the living conditions on mood in a dose-
dependent manner as sociodemographic characteristics modify
treatment response in the same direction in the two dose groups,
but in the 40 mg per day dose group the effect is much larger and
reaches statistical signiﬁcance. In addition, the magnitude of the
inﬂuence of the living conditions on mood is much greater—up to
37-fold—in the 40 compared to the 20 mg per day dose group.
These results support the undirected susceptibility to change
hypothesis,2 which predicts that, as SSRI increases the suscept-
ibility to the environment, treatment outcome is more profoundly
affected by the quality of the living conditions in patients
receiving high dosages of SSRIs.
The STAR*D clinical trial provides a unique opportunity to
investigate the role of citalopram as ampliﬁer of the inﬂuence of
the living conditions on mood. It has allowed to consider a
subpopulation of patients with similar MDD severity and over-
lapping treatment history in order to analyze the ampliﬁcation of
the inﬂuence of the sociodemographic features induced by
different dosages of citalopram. Given the clear ethical limitations
to perform a clinical trial aimed at directly measuring the effects of
the SSRIs in amplifying the beneﬁcial, but especially the
detrimental effects of the environment in patients, the STAR*D
data set is the best alternative to test the undirected susceptibility
to change hypothesis. In addition, the STAR*D clinical trial is the
largest ecologically valid 'real world' study of outpatients with
nonpsychotic major depressive disorder to date.1,19
Sociodemographic characteristics modiﬁed treatment outcome
in the same direction in the two dose groups, but these changes
did not reach statistical signiﬁcance in the 20 mg per day dose
group. By contrast, in the 40 mg per day dose group, each one of
ﬁve sociodemographic characteristics—income, education, ethni-
city, insurance and employment—signiﬁcantly affected treatment
outcome. In addition, the magnitude of the effect of the
sociodemographic characteristics on mood, measured as the
percent of patients showing a positive outcome when exposed to
a favorable environment, was dose-dependent. In particular, the
inﬂuence of the living conditions was much greater in the 40 than
in the 20 mg per day dose group: improvement rate went from a
minimum of ﬁvefold for employment status to a maximum of 37-
fold for education while remission rate went from twofold for
education to eightfold for income.
It is worth noting that, in line with our hypothesis and with
previous studies showing that a favorable and supportive
environment increases antidepressant efﬁcacy,1,10,11,13,20 the
present results indicate not only that citalopram ampliﬁes the
inﬂuence of the living conditions on mood, but also that the
quality of the living environment drives the change in mood. In
particular, in the 40 mg per day dose group, where this change
reaches statistical signiﬁcance, improvement and remission were
shown at signiﬁcantly higher rates by patients living in conditions
associated with a high quality of life, such as having a working
employment status, more than 16 years of education and a high
income. The exception concerns insurance where those indivi-
duals having public insurance showed the worse outcome, even
compared to those having no insurance.21 This is concordant with
previous studies reporting, for instance, that having public
insurance predicts the highest attrition.17 In addition, higher rates
of improvement and remission were associated with being of
Caucasian ethnicity. The sociodemographic characteristics here
found to affect treatment outcome have been previously shown
to both determine rates of major depression morbidity and
mortality22 and affect SSRI outcome.1 According to our
hypothesis,2 even a worsening of symptomatology could be
predicted when citalopram treatment is administered in an
adverse environment. However, only a very limited worsening of
the QIDS-SR score was expected in patients receiving the
treatment while living in an unfavorable condition (Figure 1)
because of the implementation of the STAR*D guidelines for
discontinuing participants, which recommend that patients drop
out of the study when clinicians consider that discontinuation is in
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the best interest of the participant. Nevertheless, an effect of
treatment, both for better and for worse,23 can be appreciated
when considering the percent of patients showing improvement
or worsening according to the quality of the living conditions in
the two dose groups (Supplementary Figure S2). Indeed, the 40,
compared to 20 mg per day dose, leads to an increase not only of
the percent of improvements in patients living in a favorable
environment, but also of the percent of worsening in patients
Table 2. Baseline sociodemographic characteristics associated with percentage of patients improved by citalopram dosea
Characteristics 20 mg per die; N= 357 (60.4%) ORb P-value 40 mg per die; N=234 (39.6%) ORb P-value
Improved % Not improved % Improved % Not improved %
Overall 56.9 43.1 54.7 45.3
Ethnicity 0.5750 0.1150
Non-Caucasianc 54.6 45.4 0.88 45.6 54.4 0.62
Caucasian 57.8 42.2 57.6 42.4
Sex 0.4069 0.2371
Female 58.6 41.4 1.20 57.9 42.1 1.37
Male 54.1 45.9 50.0 50.0
Marital status 0.1300 0.8100
No more married 71.4 28.6 1.68 54.2 45.8 0.80
Never married 57.0 43.0 0.89 59.3 40.7 0.98
Married 59.9 40.2 59.8 40.2
Employment status 0.5790 0.0219
Unemployed and retired 60.0 40.0 0.87 48.0 52.0 0.50
Employed 63.2 36.8 64.9 35.1
Educationd 0.9336 0.0053
oCollege 62.2 37.8 1.02 50.0 50.0 0.42
⩾College 61.7 38.3 70.7 29.3
Incomee 0.7200 0.0100
Low 54.3 45.7 0.87 43.3 56.7 0.37
Middle 59.7 40.4 1.08 50.6 49.4 0.49
High 57.8 42.2 67.5 32.5
Experienced traumatic event 0.4731 0.2100
No 58.1 41.9 1.17 51.5 48.5 0.71
Yes 54.3 45.7 59.8 40.2
Witnessed traumatic event 0.2660 0.1130
No 58.5 41.5 1.29 51.8 48.2 0.63
Yes 52.2 47.8 63.2 36.8
Drug abuse 0.9540 0.2950
No 52.1 48.0 1.09 46.4 53.6 0.29
Yes 50.0 50.0 75.0 25.0
Insurance status 0.8300 0.0031
Public insurance 68.0 32.0 1.33 14.3 85.7 0.08
No insurance 62.1 37.9 1.02 53.9 46.1 0.57
Private insurance 61.6 38.4 67.3 32.7
Mean (s.d.) Mean (s.d.) ORb P-value Mean (s.d.) Mean (s.d.) ORb P-value
Age (years; units= 10)f 40.6 (13.5) 42.3 (13.7) 0.91 0.2326 40.2 (12.6) 42.2 (12.9) 0.88 0.2200
Years of education (units= 4)f 14.2 (3.4) 14.3 (3.3) 0.98 0.8610 14.9 (3.0) 13.9 (2.9) 1.53 0.0402
Income ($ per month; units= 1000)f 2718 (2644) 2606 (2973) 1.01 0.7100 3483 (5446) 2385 (3279) 1.08 0.0940
Age at onset of ﬁrst MDE (units= 10) f 26.8 (14.6) 27.3 (15.8) 0.98 0.7860 24.7 (13.2) 25.5 (14.6) 0.96 0.6630
Number of MDEs (units= 5) f 4.9 (8.3) 5.7 (6.9) 0.92 0.2287 4.6 (6.3) 7.7 (14.6) 0.86 0.0436
QIDS-SR16 (difference W4− Enroll; units= 1)
f − 6.1 (4.1) − 6.3 (3.7) 1.01 0.7080 − 5.7 (3.8) − 7.6 (3.8) 1.13 0.0005
Abbreviations: MDE, major depressive episode; OR, odds ratio; QIDS-SR16, Quick Inventory of Depressive Symptomatology-Self-Report. aImprovement was
measured as a reduction ⩾ 1 in 16-item QIDS-SR16 score between weeks 4 and 6. bFor characteristics for which the measurement is categorical, the comparison
is with the group listed last under the category or with the opposite characteristic. For characteristics for which the measurement is continuous, the odds ratio
is relative to an increase in the measurement by the number of units indicated. cAsian, American Indian or Alaskan Native, Native Hawaiian/Other Paciﬁc
Islander or multiracial. doCollege=⩽ 16 years of schooling; ⩾College=⩾ 16 years of schooling. eLow=monthly gain ⩽ $1000, Middle=monthly gain $1000–
$2500, High=monthly gain 4$2500. fUnits are relevant to odds ratios only OR, MDE.
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living in an unfavorable environment. For instance, in the 20 mg
per day dose group, patients with a college degree showing an
improvement were 62% and patients with a high school degree
showing a worsening were 21%. In the 40 mg per day group,
these percent rise up, respectively, to 71% and 35%. As further
example, in the 20 mg per day dose group, patients with a high
income showing an improvement were 58% and patients
with a low income showing a worsening were 35% while, in the
Table 3. Baseline sociodemographic characteristics associated with remission by citalopram dosea
Characteristics 20 mg per die; N=357
(60.4%)
ORb P-value 40 mg per die; N= 234
(39.6%)
ORb P-value
REM % NO REM % REM % NO REM %
Overall 35.9 64.1 24.4 75.6
Ethnicity 0.8622 0.0872
Non-Caucasianc 35.2 64.8 0.96 15.8 84.2 0.50
Caucasian 36.1 63.9 27.1 72.9
Sex 0.5845 0.1300
Female 36.9 63.1 1.13 27.9 72.1 1.63
Male 34.1 65.9 19.1 80.9
Marital status 0.2900 0.8200
No more married 45.5 54.5 1.41 22.9 77.1 0.83
Never married 33.7 66.3 0.86 22.2 77.8 0.80
Married 37.1 62.9 26.4 73.6
Employment status 0.5970 0.0326
Unemployed and retired 36.4 63.6 0.88 16.0 84.0 0.45
Employed 39.5 60.5 29.8 70.2
Educationd 0.2155 0.0484
oCollege 41.1 58.9 1.36 19.3 80.7 0.51
⩾College 33.9 66.1 32.0 68.0
Incomee 0.2000 0.1100
Low 33.3 66.7 1.02 17.9 82.1 0.48
Middle 43.0 57.0 1.54 19.8 80.2 0.54
High 32.8 67.2 31.3 68.8
Experienced traumatic event 0.3318 0.5510
No 37.4 62.6 1.25 23.1 76.9 0.83
Yes 32.5 67.5 26.5 73.5
Witnessed traumatic event 0.3520 0.6650
No 36.9 63.1 1.25 23.8 76.2 0.87
Yes 31.9 68.1 26.5 73.5
Drug abuse 0.6800 0.1820
No 35.6 64.4 0.55 19.6 80.4 0.24
Yes 50.0 50.0 50.0 50.0
Insurance status 0.9000 0.1500
No insurance 39.8 60.2 1.12 18.4 81.6 0.49
Public insurance 40.0 60.0 1.13 0.0 100.0 0.00
Private insurance 37.2 62.8 31.6 68.4
Mean (s.d.) Mean (s.d.) ORb P-value Mean (s.d.) Mean (s.d.) ORb P-value
Age (years; units= 10)f 39.5 (13.0) 42.4 (13.8) 0.85 0.0565 38.2 (13.4) 42.1 (12.4) 0.78 0.0470
Years of education (units= 4)f 13.8 (3.4) 14.5 (3.3) 0.78 0.0805 14.6 (3.3) 14.4 (2.9) 1.08 0.7421
Income ($/month; units= 1000)f 2543 (2445) 2743 (2964) 0.97 0.5208 3506 (4367) 2824 (4682) 1.03 0.3620
Age at onset of ﬁrst MDE (units= 10)f 27.0 (15.0) 27.0 (15.2) 1.00 0.9722 25.9 (13.0) 24.9 (14.1) 1.05 0.6320
Number of MDEs (units= 5)f 3.7 (6.8) 6.1 (8.0) 0.76 0.0152 4.2 (7.5) 6.6 (11.7) 0.86 0.1980
QIDS-SR16 (difference W4-Enroll; units= 1)
f − 6.7 (4.2) − 5.9 (3.7) 0.95 0.0765 − 6.4 (4.2) − 6.6 (3.8) 1.01 0.7392
Abbreviations: MDE, major depressive episode; OR, odds ratio; QIDS-SR16, Quick Inventory of Depressive Symptomatology Self-Report; REM, remission.
aRemission was deﬁned as a score ⩽ 5 at week 6 on the 16-item QIDS-SR16. bFor characteristics for which the measurement is categorical, the comparison is
with the group listed last under the category or with the opposite characteristic. For characteristics for which the measurement is continuous, the odds ratio is
relative to an increase in the measurement by the number of units indicated. cAsian, American Indian or Alaskan Native, Native Hawaiian/Other Paciﬁc Islander
or multiracial. doCollege=⩽ 16 years of schooling; ⩾College=⩾ 16 years of schooling. eLow=monthly gain ⩽ $1000; Middle=monthly gain $1000–$2500;
High=monthly gain4$2500. fUnits are relevant to odds ratios only OR, MDE.
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40 mg per day group, these are, respectively, 68% and 40%
(Supplementary Figure S2).
Taking into account the role of SSRIs as ampliﬁer of the
inﬂuence of living conditions on mood—and, consequently, the
quality of the environment as a moderator of SSRI treatment
outcome24—may explain the inconsistency of the ﬁndings in the
literature about SSRI efﬁcacy. Indeed, overlooking the environ-
ment as the key stratifying factor in treatment response might
have led to the reported contradictory results in antidepressant
outcome. The conceptual shift in considering the action of SSRIs
from being the causative factor for recovering from major
depression to acting as a permissive factor for the inﬂuence of
the living conditions on the psychopathology allows to reconcile
experimental and clinical data that apparently do not ﬁt together.2
For instance, the theoretical framework currently available in
the literature leads to the paradox that the same molecular
mechanism of action has two opposite outcomes: high extracellular
serotonin levels are beneﬁcial when induced by SSRI administra-
tion, but confer a high risk to develop psychopathology when
associated to the s variant of the serotonin-transporter-linked
polymorphic region (5-HTTLPR). This discordant picture can be
coherently interpreted in light of our results and the undirected
susceptibility to change hypothesis, positing that high serotonin
levels lead to increased plasticity and thus to high susceptibility to
change, which may promote either an improvement or a
worsening, according to the quality of the environment.2 It is
worth noting that the effects of citalopram described in the
present paper may represent only part of the action of SSRIs on
mood as the main target of these drugs, that is, the serotoninergic
system, has a high molecular complexity and is involved in a wide
range of physiological functions.
The major limitation of the present study is the short time frame
(2-week period) over which data of the STAR*D clinical trial have
been extracted. This period had to be chosen because it is the
only one allowing to consider patients with overlapping clinical
history. Longer or different treatment periods or other patient
groups would have not allowed to keep data validity. By contrast,
the fact that coherent signiﬁcant results have been found in such
a short time frame suggests that the described phenomenon is
robust. Further limitations include open treatment design, the use
-2
-1
0
< college ≥ college
∆ 
Q
ID
S
-S
R
16
0
-2
-1
*
***
Education Income
middlelower higher
20 mg/d 40 mg/d40 mg/d   20 mg/d
employedunemployed
Caucasiannon-Caucasian
-2
-1
0
-1
0
1
-2
∆ 
Q
ID
S
-S
R
16
∆ 
Q
ID
S
-S
R
16
*
Employment
Ethnicity
40 mg/d20 mg/d
40 mg/d20 mg/d
privatepublic no
0
1
2
-2
-1
*
Insurance
marriedneverno more
-2
-1
0
Marital Status
40 mg/d20 mg/d
40 mg/d20 mg/d
Figure 1. Variation in the QIDS-SR16 score, measured between weeks 4 and 6, in patients receiving either the 20 or 40 mg per day dose.
Negative values indicate a reduction of the QIDS-SR16 score, that is, an improvement of the patient’s mental health condition. Only patients
receiving the 40 mg per day dose showed a variation in the QIDS-SR16 signiﬁcantly moderated by the sociodemographic characteristics.
* Indicates difference with the ﬁrst group; *Po0.05 and ***Po0.001. QIDS-SR16, Quick Inventory of Depressive Symptomatology Self-Report.
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of a single antidepressant agent (citalopram) and the lack of
placebo control. Although data analyses did not include correction
for multiple comparisons, the overall consistence of the results
support their reliability. It is worth noting that depression
treatment disparities experienced by different ethnicities may
result from stigma, clinician failure to engage with the patient,
poor patient activation, treatment adherence and other factors,
including biological differences.25
In conclusion, acknowledging the role of SSRIs as ampliﬁer of the
inﬂuence of the living conditions on mood represents a critical step
in developing a personalized medicine approach aimed at better
matching patients with treatment and avoiding potential harmful
consequences. The control of the patients' living environment could
be achieved by training patients to cope with harsh conditions, for
instance, through cognitive behavioral therapy,26 or taking them in
charge through appropriate specialized services, as it is unlikely that
people can rapidly and effectively change their living milieu. The
cost of this approach is limited as no new psychoactive molecules
need to be developed, while the beneﬁts for the patients could be
substantial. Finally, the undirected susceptibility to change hypo-
thesis may contribute building a new theoretical framework
capable to integrate the 'chemical imbalance theory' with other
hypotheses acknowledging the importance of social–psychological
factors in MDD, as both approaches are needed to explain the
mechanisms underlying the recovery from the disease.
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